Form 4: Revance Therapeutics CFO Tobin Schilke Acquires Shares Under Employee Stock Purchase Plan

Revance Therapeutics' CFO, Tobin Schilke, acquired 1,000 shares of common stock through the company's Employee Stock Purchase Plan on December 31, 2024.

Summary

• On December 31, 2024, Tobin Schilke, CFO of Revance Therapeutics, acquired 1,000 shares of common stock.
• The acquisition was made through the company's 2014 Employee Stock Purchase Plan.
• The price per share was $2.1845.
• Following the transaction, Mr. Schilke beneficially owns 194,666 shares of Revance Therapeutics common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a routine transaction. The CFO purchasing shares can be seen as a slightly positive sign, but it's not a major event.

Positives

• The CFO's participation in the Employee Stock Purchase Plan could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This type of transaction is common for executives who participate in employee stock purchase plans. It's a way for them to increase their ownership stake in the company.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals insider confidence.

Key Dates

Keywords

Revance Therapeutics, RVNC, Tobin Schilke, CFO, Employee Stock Purchase Plan, Stock Acquisition, Beneficial Ownership, Form 4